MORGAN STANLEY PLC/CALL/INCYTE CO./70/0.5/20.12.24 | Real-time Bid/Ask 10:17:14 23/05/2024 BST | ||
| 1.07 EUR / 1.22 EUR | +25.82% |
|
| Current month | +85.71% | ||
| 1 month | +54.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 0.91 | -4.21% |
| 21/05/24 | 0.95 | +7.95% |
| 20/05/24 | 0.88 | +31.34% |
| 17/05/24 | 0.67 | -10.67% |
| 16/05/24 | 0.75 | +2.74% |
Delayed Quote Börse Stuttgart
Last update May 22, 2024 at 05:59 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME9H30 |
| ISIN | DE000ME9H304 |
| Date issued | 01/03/2024 |
| Strike | 70 $ |
| Maturity | 20/12/2024 (212 Days) |
| Parity | 2 : 1 |
| Emission price | 1.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.73 € |
|---|---|
| Lowest since issue | 0.45 € |
| Spread | 0.15 € |
| Spread % | 12.30% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
58.2
USD
Average target price
73.65
USD
Spread / Average Target
+26.54%
- Stock Market
- Warrants
- Warrant
